Eli Lilly’s ‘game-changing’ diabetes drug could boost the stock, SVB Securities says

Eli Lilly ‘s new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company’s stock, according to SVB Securities. Analyst David Risinger initiated coverage of Eli Lilly with an outperform rating, saying in a Sunday note that investors are failing to price in the potential of tirzepatide, or Mounjaro, as treatments for diabetes and obesity. Mounjaro was recently approved by the Food and Drug Administration to treat Type 2 diabetes, and is being investigated for potential use for obesity. “We believe that consensus underappreciates the sales potential for Lilly’s recently-approved tirzepatide (brand name Mounjaro) for diabetes and obesity, and we expect upward estimate revisions to drive stock outperformance,” Risinger wrote. SVB Securities also issued a $341 price target, representing nearly 14% upside from Friday’s closing price. Shares of Eli Lilly have outperformed this year, up 8% year to date while the S & P 500 is down 18% over the same time period. However, analysts believe they have further to go, especially if tirzepatide is covered by employers for weight loss. “Employers historically hesitated to cover obesity drugs because they view them as aesthetic agents which did not yield meaningful health benefits,” Risinger wrote. “But what is game-changing about tirzepatide is its ability to transform overall patient health by driving such significant weight loss.” SVB analysts are also bullish on the company’s drug pipeline beyond tirzepatide. The company has more treatments addressing diabetes and obesity, as well as cardiovascular disease, the note said. Notably, they’re more skeptical on the company’s treatment for Alzheimer’s. “We are recommending LLY shares despite the stock’s high valuation because we believe the company’s ability to transform the treatment of obesity is underappreciated, and even if Alzheimer’s news flow is negative, we see meaningful positive optionality in other pipeline candidates,” the note read. Shares of Eli Lilly popped 1% in Monday premarket trading. —CNBC’s Michael Bloom contributed to this report.

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020.

Mike Blake | Reuters

Eli Lilly’s new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company’s stock, according to SVB Securities.

Source

Business

Top five tax changes for the wealthy in Trump’s ‘big beautiful bill’

July 3, 2025

A view of the US Capitol in Washington, DC, on June 30, 2025. Jim Watson | Afp | Getty Images The wealthy will likely see a host of new tax breaks in President Donald Trump’s “big beautiful bill,” along with permanent extensions of many of the 2017 tax cuts, according to tax experts. Taxpayers earning […]

Business

Retailers avoided a worst case scenario in Vietnam. But executives say Trump’s trade deal could still hit consumers

July 3, 2025

The retail industry is breathing a sigh of relief after it appeared to avoid the worst case scenario on Vietnam tariffs. But some executives believe the tentative trade deal President Donald Trump announced Wednesday is still bad for business and could have a chilling effect on consumer spending. “It’s a lot better news than where […]

Business

Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

July 3, 2025

U.S. Vice President Kamala Harris speaks on stage with Essence CEO Caroline Wanga at the Global Black Economic Forum during the 30th annual Essence Festival of Culture at the Ernest N. Morial Convention Center on July 6, 2024 in New Orleans, Louisiana. Michael Democker | Getty Images News | Getty Images In a year when […]